تخطي إلى المحتوى

Novartis Canada’s statement on CADTH draft recommendations for LEQVIO® (inclisiran)

MONTRÉAL, March 21, 2024 /CNW/ – Novartis Pharmaceuticals Canada Inc. (Novartis Canada) is deeply disappointed with the draft recommendations of the Canadian Drug Expert Committee (CDEC) issued by the Canadian Agency for Drugs and Technologies in Health (CADTH) for LEQVIO® (inclisiran). As an organization, Novartis respects the process conducted by CADTH but at the same time holds a firm belief in the value that LEQVIO brings to patients, clinicians, and the healthcare system. Globally, LEQVIO is widely accessible in 94 countries,4 with public reimbursement in 31 countries,5 and has positively impacted over 178,000 patients.5 https://www.cadth.ca/open-calls-input-and-feedback-0

Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder

BNC210 demonstrated a statistically significant improvement in post-traumatic stress disorder (PTSD) symptom severity with a clinically meaningful effect size suggesting a potential advantage over approved medications. Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder

TELA Bio تعلن عن الإطلاق التجاري في الولايات المتحدة لـ LIQUIFIX™ – المادة اللاصقة السائلة الوحيدة المعتمدة من إدارة الغذاء والدواء للاستخدام الداخلي في جراحة الفتق

Strong and secure, LIQUIFIX is the first approved adhesive-based product to affix mesh without penetrating patient tissue Strong and secure, LIQUIFIX is the first approved adhesive-based product to affix mesh without penetrating patient tissue TELA Bio Announces U.S. Commercial Launch of LIQUIFIX™ – the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia Surgery

Bavarian Nordic A/S – Notice Convening Annual General Meeting

COPENHAGEN, Denmark, March 21, 2024 – Pursuant to Articles 10-14 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the Annual General Meeting to be held on Bavarian Nordic A/S – Notice Convening Annual General Meeting

CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors

SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Zhen Su, M.D., M.B.A., an experienced physician executive and leader in the development of oncology therapeutics, to the company’s board of directors. CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors

تحدد وزارة الزراعة الأمريكية (USDA-APHIS) أن أصناف الكانولا الغنية بالأوميغا 3 من شركة Yield10 Bioscience يمكن زراعتها وتربيتها في الولايات المتحدة.

Yield10 Bioscience achieves significant milestone enabling ramp-up to commercial scale production of omega-3 fatty acids in Camelina in the United States. USDA-APHIS Determines that Yield10 Bioscience’s Omega-3 Camelina Varieties May Be Planted and Bred in the United States

دياديك ستحضر فعالية مستقبل تكنولوجيا الأغذية 21 – 22 مارس 2024 في سان فرانسيسكو، كاليفورنيا

JUPITER, Fla., March 21, 2024 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that Joseph Hazelton, Chief Business Officer and Doug Pace, Executive Vice President of Business Development will be attending the Future Food-Tech “Innovation & Investment from Farm to Fork” event March 21 – 22, 2024 at the San Francisco Marriott Marquis in California. Dyadic to Attend Future Food Tech Event March 21 – 22, 2024 in San Francisco, California

معهد Fraunhofer IPMS يطور نظامًا جديدًا متعدد المستشعرات لتحليل المياه

Der kapazitive Leitfähigkeitssensor der Fraunhofer IPMS beruht auf einer metallischen 4-Elektroden Anordnung, die mit einem chemisch und mechanisch robusten Metalloxid beschichtet ist. Das Messmedium kommt somit nur mit dem Oxid, nicht aber mit dem Elektrodenmetall in Kontakt. Es kommt bei der Messung somit nicht zur Freisetzung von Metallionen oder zu deren Verschmutzung. Die Sensoren haben eine Zellkonstante von 0.8 bis 1.1 cm-1 und sind bei einer Messfrequenz von 100 Hz bis 1MHz einsetzbar. Der neuartige ISFET des Fraunhofer IPMS beruht auf der Metal-Oxid-Semiconductor (MOS) Feldeffekttransistortechnologie, wobei der medienberührende Sensorbereich aus einer amphoteren Metalloxidschicht besteht. An dieser Schicht lagern sich entsprechend des pH-Wertes Hydronium- oder Hydroxidionen aus dem Messmedium reversibel an (pH-sensitive Layer). Als Messsignal wird dann die Spannung (VGS) zwischen der Sourceelektrode und der Gate- bzw. Referenzelektrode (Ag/AgCl in 3M KCl) genutzt. Teile der Ergebnisse wurden im Projekt „REISen“ erzielt,… 

more »Fraunhofer IPMS entwickelt neues Multisensorsystem für die Wasseranalytik